Study S001476

A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Trial

ClinicalTrials.gov record

Registration

Registration: NCT07153471
Acronym: ATTAIN-OA PAIN
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: SINGLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 800
Start: 2025-09-15
Primary completion: 2028-04
Lead sponsor: Eli Lilly and Company
Conditions: Osteoarthritis
Interventions: DRUG:Orforglipron; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: CTIS:2025-522631-34-00; OTHER:J2A-MC-GZPT; OTHER:J2A-MC-GZT1; OTHER:J2A-MC-GZT2; NIH:2025

Registered primary outcomes

Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score [Baseline, Week 72]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.